Oxymetazoline
Kovanaze, Rhofade, Upneeq, Visine (oxymetazoline) is a small molecule pharmaceutical. Oxymetazoline was first approved as Ocuclear on 1986-05-30. It is used to treat common cold, conjunctivitis, rhinitis, and sinusitis in the USA. The pharmaceutical is active against alpha-1A adrenergic receptor and alpha-2A adrenergic receptor. In addition, it is known to target 5-hydroxytryptamine receptor 1D, 5-hydroxytryptamine receptor 1B, alpha-2C adrenergic receptor, alpha-1B adrenergic receptor, 5-hydroxytryptamine receptor 2C, alpha-1D adrenergic receptor, and alpha-2B adrenergic receptor.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Trade Name
FDA
EMA
Rhofade, Upneeq, Visine (discontinued: Ocuclear)
CombinationsKovanaze
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Oxymetazoline hydrochloride
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| VISINE L.R. | Johnson & Johnson | N-019407 OTC | 1989-03-31 | 1 products, RLD, RS |
| RHOFADE | Mayne Group | N-208552 RX | 2017-01-18 | 1 products, RLD, RS |
| UPNEEQ | RVL Pharmaceuticals | N-212520 RX | 2020-07-08 | 1 products, RLD, RS |
Show 1 discontinued
Oxymetazoline hydrochloride
+
Tetracaine hydrochloride
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| KOVANAZE | St Renatus | N-208032 RX | 2016-06-29 | 1 products, RLD, RS |
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| mucinex | OTC monograph final | 2010-10-07 |
| mucinex childrens stuffy nose | OTC monograph final | 2022-01-11 |
| mucinex sinus-max | OTC monograph final | 2022-01-07 |
| mucinex sinus-max pressure, pain and cough and mucinex sinus-max severe congestion relief clear and cool | C200263 | 2023-10-02 |
| nasal decongestant | C200263 | 2024-01-01 |
| vicks sinex | C200263 | 2023-10-16 |
| vicks sinex severe | C200263 | 2023-10-16 |
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| common cold | EFO_0007214 | D003139 | J00 |
| conjunctivitis | — | D003231 | H10 |
| rhinitis | EFO_0008521 | D012220 | J31 |
| sinusitis | EFO_0007486 | D012852 | J32 |
Agency Specific
FDA
EMA
Expiration | Code | ||
|---|---|---|---|
OXYMETAZOLINE HYDROCHLORIDE, UPNEEQ, RVL PHARMS | |||
| 2023-07-08 | NP | ||
Patent Expiration
Patent | Expires | Flag | FDA Information |
|---|---|---|---|
| Oxymetazoline Hydrochloride, Upneeq, Rvl Pharms | |||
| 10799481 | 2039-12-16 | U-2849 | |
| 10814001 | 2039-12-16 | DP | |
| 10898573 | 2039-12-16 | DP | |
| 10940138 | 2039-12-16 | U-2849 | |
| 11103482 | 2039-12-16 | DP | |
| 11311515 | 2039-12-16 | DP | |
| 11324722 | 2039-12-16 | U-2849 | |
| 11541036 | 2039-12-16 | DP | |
| 8357714 | 2031-08-26 | U-2849 | |
| 9867808 | 2031-08-26 | U-2849 | |
| 10912765 | 2031-08-26 | U-2849 | |
| Oxymetazoline Hydrochloride, Rhofade, Mayne Pharma | |||
| 9974773 | 2035-06-11 | U-2306 | |
| 10335391 | 2035-06-11 | U-2567 | |
| 10751325 | 2035-06-11 | U-2921 | |
| 11517560 | 2035-06-11 | U-3494 | |
| 8883838 | 2031-12-01 | DP | |
| 7812049 | 2028-05-02 | U-1959 | |
| 8420688 | 2024-08-02 | U-1959 | |
| 8815929 | 2024-01-22 | U-1959 | |
| Oxymetazoline Hydrochloride / Tetracaine Hydrochloride, Kovanaze, St Renatus | |||
| 8580282 | 2030-04-02 | DP | U-1876 |
| 9308191 | 2030-04-02 | DP | U-1876 |
ATC Codes
D: Dermatologicals
— D11: Other dermatological preparations in atc
— D11A: Other dermatological preparations in atc
— D11AX: Other dermatological preparations in atc
— D11AX27: Oxymetazoline
R: Respiratory system drugs
— R01: Nasal preparations
— R01A: Decongestants and other nasal preparations for topical use
— R01AA: Sympathomimetics, plain
— R01AA05: Oxymetazoline
— R01AB: Sympathomimetics, combinations excl. corticosteroids
— R01AB07: Oxymetazoline
S: Sensory organ drugs
— S01: Ophthalmologicals
— S01G: Decongestants and antiallergics
— S01GA: Sympathomimetics used as decongestants
— S01GA04: Oxymetazoline
HCPCS
No data
Clinical
Clinical Trials
764 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Healthy volunteers/patients | — | — | — | 119 | 1 | — | 2 | 8 | 129 |
| Hypotension | D007022 | EFO_0005251 | I95 | 3 | 5 | 5 | 17 | 23 | 50 |
| Asthma | D001249 | EFO_0000270 | J45 | 15 | 8 | 2 | 1 | 1 | 27 |
| Chronic obstructive pulmonary disease | D029424 | EFO_0000341 | J44.9 | 9 | 6 | 4 | 2 | 1 | 22 |
| Anesthesia | D000758 | — | — | 1 | 5 | 4 | 5 | 7 | 22 |
| Spinal anesthesia | D000775 | — | — | — | 2 | 1 | 8 | 4 | 15 |
| Cataract | D002386 | HP_0000518 | H26.9 | — | — | 3 | 5 | 5 | 13 |
| Blood pressure | D001794 | EFO_0004325 | — | 2 | 1 | 1 | 2 | 6 | 11 |
| Vasoconstriction | D014661 | — | — | 5 | — | — | 1 | 5 | 11 |
| Allergic rhinitis | D065631 | — | J30.9 | 2 | 3 | 1 | 3 | 1 | 10 |
Show 62 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Presbyopia | D011305 | — | H52.4 | 3 | — | 1 | — | 2 | 6 |
| Respiratory tract infections | D012141 | — | J06.9 | 1 | — | 4 | — | — | 5 |
| Rhinitis | D012220 | EFO_0008521 | J31 | 1 | 1 | 2 | — | 1 | 5 |
| Spinal cord injuries | D013119 | EFO_1001919 | — | 1 | 1 | 1 | — | 3 | 5 |
| Cold temperature | D003080 | — | — | — | — | 3 | — | — | 3 |
| Inflammation | D007249 | MP_0001845 | — | — | — | 3 | — | — | 3 |
| Stroke | D020521 | EFO_0000712 | I63.9 | — | — | 2 | — | 1 | 3 |
| Fecal incontinence | D005242 | — | R15 | 2 | 1 | 1 | — | — | 3 |
| Erythema | D004890 | HP_0010783 | L53.9 | — | — | 3 | — | — | 3 |
| Eye diseases | D005128 | EFO_0003966 | H44 | — | — | 2 | — | 1 | 3 |
Show 20 more
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Parkinson disease | D010300 | EFO_0002508 | G20 | 6 | 1 | — | — | 1 | 8 |
| Type 1 diabetes mellitus | D003922 | EFO_0001359 | E10 | 2 | 1 | — | — | 2 | 5 |
| Dental caries | D003731 | EFO_0003819 | K02 | — | 3 | — | — | — | 3 |
| Periapical periodontitis | D010485 | EFO_1001391 | K04.5 | — | 3 | — | — | — | 3 |
| Post-traumatic stress disorders | D013313 | EFO_0001358 | F43.1 | — | 1 | — | — | 1 | 2 |
| Microcirculation | D008833 | — | — | — | 1 | — | — | 1 | 2 |
| Cognitive dysfunction | D060825 | HP_0001268 | G31.84 | — | 1 | — | — | 1 | 2 |
| Hypertriglyceridemia | D015228 | EFO_0004211 | — | 1 | 1 | — | — | — | 2 |
| Vasovagal syncope | D019462 | — | R55 | 1 | 1 | — | — | — | 2 |
| Regional blood flow | D012039 | — | — | — | 2 | — | — | — | 2 |
Show 22 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Therapeutic equivalency | D013810 | — | — | 9 | — | — | — | — | 9 |
| Pharmacokinetics | D010599 | — | — | 8 | — | — | — | — | 8 |
| Cardiovascular diseases | D002318 | HP_0001626 | — | 2 | — | — | — | 5 | 7 |
| Biological availability | D001682 | — | — | 4 | — | — | — | — | 4 |
| Postural orthostatic tachycardia syndrome | D054972 | — | G90.A | 1 | — | — | — | 3 | 4 |
| Hypertension | D006973 | EFO_0000537 | I10 | 2 | — | — | — | 1 | 3 |
| Essential hypertension | D000075222 | — | I10 | 3 | — | — | — | — | 3 |
| Orthostatic hypotension | D007024 | — | I95.1 | 2 | — | — | — | 1 | 3 |
| Heart failure | D006333 | HP_0001635 | I50 | 2 | — | — | — | 1 | 3 |
| Hypoxia | D000860 | HP_0012418 | R09.02 | 1 | — | — | — | 2 | 3 |
Show 45 more
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Aging | D000375 | GO_0007568 | R41.81 | — | — | — | — | 3 | 3 |
| Carotid endarterectomy | D016894 | — | — | — | — | — | — | 3 | 3 |
| Overweight | D050177 | — | E66.3 | — | — | — | — | 2 | 2 |
| Hip fractures | D006620 | EFO_0003964 | S72.00 | — | — | — | — | 2 | 2 |
| Urinary tract infections | D014552 | EFO_0003103 | N39.0 | — | — | — | — | 2 | 2 |
| Knee osteoarthritis | D020370 | EFO_0004616 | M17 | — | — | — | — | 2 | 2 |
| Sinusitis | D012852 | EFO_0007486 | J32 | — | — | — | — | 2 | 2 |
| Neck pain | D019547 | HP_0030833 | M54.2 | — | — | — | — | 2 | 2 |
| Autonomic dysreflexia | D020211 | EFO_1001762 | G90.4 | — | — | — | — | 2 | 2 |
| Coronary artery disease | D003324 | — | I25.1 | — | — | — | — | 2 | 2 |
Show 92 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Oxymetazoline |
| INN | oxymetazoline |
| Description | Oxymetazoline is a member of the class of phenols that is 2,4-dimethylphenol which is substituted at positions 3 and 6 by 4,5-dihydro-1H-imidazol-2-ylmethyl and tert-butyl groups, respectively. A direct-acting sympathomimetic with marked alpha-adrenergic activity, it is a vasoconstrictor that is used (generally as the hydrochloride salt) to relieve nasal congestion. It has a role as an alpha-adrenergic agonist, a sympathomimetic agent, a nasal decongestant and a vasoconstrictor agent. It is a member of phenols, a carboxamidine and a member of imidazolines. It is a conjugate base of an oxymetazoline(1+). |
| Classification | Small molecule |
| Drug class | antihistamines/local vasoconstrictors (antazoline type) |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | Cc1cc(C(C)(C)C)c(O)c(C)c1CC1=NCCN1 |
Identifiers
| PDB | — |
| CAS-ID | 1491-59-4 |
| RxCUI | — |
| ChEMBL ID | CHEMBL762 |
| ChEBI ID | 7862 |
| PubChem CID | 4636 |
| DrugBank | DB00935 |
| UNII ID | 8VLN5B44ZY (ChemIDplus, GSRS) |
Target
Agency Approved
ADRA1A
ADRA1A
ADRA2A
ADRA2A
Organism
Homo sapiens
Gene name
ADRA1A
Gene synonyms
ADRA1C
NCBI Gene ID
Protein name
alpha-1A adrenergic receptor
Protein synonyms
Alpha-1A adrenoceptor, Alpha-1A adrenoreceptor, Alpha-1C adrenergic receptor, Alpha-adrenergic receptor 1c, G protein coupled receptor
Uniprot ID
Mouse ortholog
Adra1a (11549)
alpha-1A adrenergic receptor (Q8BV77)
Alternate
HTR1D
HTR1D
HTR1B
HTR1B
ADRA2C
ADRA2C
ADRA1B
ADRA1B
HTR2C
HTR2C
ADRA1D
ADRA1D
ADRA2B
ADRA2B
Organism
Homo sapiens
Gene name
HTR1D
Gene synonyms
HTR1DA, HTRL
NCBI Gene ID
Protein name
5-hydroxytryptamine receptor 1D
Protein synonyms
5-HT-1D, 5-HT-1D-alpha, 5-hydroxytryptamine (serotonin) receptor 1D, G protein-coupled, Serotonin 1D alpha receptor, Serotonin receptor 1D
Uniprot ID
Mouse ortholog
Htr1d (15552)
5-hydroxytryptamine receptor 1D (Q8BUW7)
Variants
No data
Financial
Revenue by drug
$
€
£
₣
Rhofade – Aclaris Therapeutics
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Rhofade – Novan
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Estimated US medical usage
Oxymetazoline
Total medical expenditures per year (USD, in millions)
Mock data
Subscribe for the real data
Subscribe for the real data
Number of persons purchased
Mock data
Subscribe for the real data
Subscribe for the real data
Number of purchases
Mock data
Subscribe for the real data
Subscribe for the real data
Refill frequency
Mock data
Subscribe for the real data
Subscribe for the real data
Price per prescription (USD)
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 1,609 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
4,002 adverse events reported
View more details
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use